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Objective: Soy phytoestrogens are suggested to impair thyroid function but the effects
of pharmacological doses of soy phytoestrogens are unknown; therefore, this study was
performed to determine the effect of high dose soy phytoestrogens (66mg) on thyroid
function in subclinical hypothyroidism.
Design and setting: Randomized, double-blind, crossover study.
Participants: Forty four patients with subclinical hypothyroidism.
Intervention: Participants were randomly allocated to either 66mg phytoestrogen
with 30 g soy protein (active) or 0mg phytoestrogen with 30 g soy protein (placebo)
supplementation for 8 weeks, washed out for 8 weeks and then crossed over for another
8 week period.
Main outcome measures: The primary outcome was progression to overt
hypothyroidism with the secondary outcome measures were changes in thyroid function
tests.
Results: Two patients in this trial progressed into overt hypothyroidism after high dose
phytoestrogen supplementation. TSH, free thyroxine and triiodothyronine did not differ
between groups.
Conclusion: A pharmacological dose of 66mg of soy phytoestrogens did not increase
the overt thyroid failure rate or alter thyroid function tests in patients with subclinical
hypothyroidism.
Keywords: subclinical hypothyroidisim, phytoestrogen, isoflavones, daidzein, genistein glucosides
INTRODUCTION
Soy foods is becoming increasingly popular in Western countries due to their potential health
effects. Postulated health benefits of soy, due to their phytoestrogen components, include protection
against ischemic heart disease (1–3), prostate and breast cancer (4–6), bone health (7), and
alleviation of menopausal symptoms (8). Interest in the health benefits of phytoestrogens has
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led to the development of supplements containing phytoestrogen
and the fortification of foods with soy phytoestrogens (9, 10).
However, there are concerns that soy may adversely affect thyroid
in susceptible individuals (11–13).
It is speculated that for certain subsets of the population
soy isoflavones may be detrimental. Environmental factors are
determinant for the appearance thyroid diseases in susceptible
individuals. Dietary factors such as increased iodine intake,
selenium, and vitamin D deficiency, exposure to radiation are
environmental factors known to predispose to thyroid disorders
(14). Goiter has been seen in infants fed soy formula; this
is usually reversed by changing to cows’ milk or iodine-
supplemented diets (15, 16). In vitro research (17, 18) and in
rodents (19, 20) supplemented with isoflavones suggests that soy
can have a detrimental effect in thyroid. There are concerns that
they may compromise thyroid function (18, 21), especially in
patients with subclinical hypothyroidism.
In a double blind cross over study in patients with subclinical
hypothyroidism with low dose phytoestrogen (30 g soy protein
with 2mg phytoestrogens, representative of Western diet),
or a high dose phytoestrogen (30 g soy protein with 16mg
phytoestrogens, representative of a vegetarian diet), there was a
threefold increased risk of developing overt hypothyroidism with
high dose phytoestrogen supplementation (13).
Dietary intake of phytoestrogens in Asian diets has been
estimated to be in the range of 30–50 mg/day of combined
phytoestrogen aglycone equivalents (22, 23). Therefore, this
double blind, cross over study was undertaken to assess the effect
of a pharmacological dose of soy phytoestrogens with subclinical
hypothyroidism who has compromised thyroid function. Soy
protein was supplemented with 0mg phytoestrogens or 66mg
phytoestrogens as a powder to be mixed with their daily food and
is a similar dose used to treat menopausal symptoms.
PATIENTS AND METHODS
Hull and East Yorkshire Ethics committee gave ethics approval
for this study. Informed written consent was obtained from
all study particpants before enrolling into the trial. Patients
with subclinical hypothyroidism (TSH value between 4.8–
10mU/L; reference range 0.5–4.7mU/L) with a free thyroxine
(fT4) within the reference range were recruited. The screening
thyroid function tests were done 4 to 8 weeks after the initial
thyroid function test measurement. A total of 69 patients
were initially identified. Patients taking drugs that might have
interfered with thyroid function, anti-hypertensives, insulin
sensitizing agents, lipid lowering medications, antibiotic use
within the previous 6 months and women planning pregnancy
were excluded. Patients who were taking vegetarian or vegan
diets were excluded. Fifteen patients were excluded because
they could not tolerate palatability of the soy preparation,
thyroid function tests normalized for six patients suggesting
transient thyroiditis, two patients had overt hypothyroidism, one
patient was lost to follow up and another patient was already
on thyroxine supplementation. Participants were instructed to
maintain their current level of physical activity throughout the
study. Participants were also instructed to avoid food products
containing soy, mineral or vitamin supplementation and over
the counter medications. Otherwise, they were encouraged to
continue their usual diet. Plasma phytoestrogens were measured
and dietary reinforcement was undertaken at each visit to ensure
compliance.
STUDY DESIGN
A double blind randomized, cross over trial was undertaken. A
total of 44 participants (age range 23–80 years; 20 males, and
24 females) were randomized; 22 patients were commenced with
the 0mg phytoestrogen with soy protein powder (30 g) and 22
patients on the 66mg phytoestrogen with soy protein powder
(30 g) per day for 8 weeks to be mixed with their food (first
phase). Participants received the alternative supplementation
for 8 weeks (second phase) after an 8 week wash out period.
Given that the half-life of thyroxine is around seven day, 8
week time period was chosen for each arm as this was the
minimum duration of phytoestrogen exposure that might have
been expected to affect thyroid function.
Participants received boxes of supplements containing the
number of sachets required for 8 weeks of supplementation plus
six reserve sachets in case of study material loss or any delay in
their study visits.
After baseline tests, the participants were randomly
allocated to either 66mg phytoestrogen or 0mg phytoestrogen
supplementation, by a computer generated randomization list.
Each randomization number corresponded with 1 of the 2
possible arms. Labeling of the identical study preparation was
performed by personnel not involved in the study. Compliance
was measured by counting the returned sachets.
The primary outcome of the trial was progression to overt
hypothyroidism while secondary outcome measures were lipids,
hsCRP, blood pressure and HOMA-IR. Overt hypothyroidism
was defined as a combination of TSH > 4.7 mU/L and free
thyroxine <9 pmol/L. The flow chart of participants is given in
Figure 1.
PHYTOESTROGEN COMPOSITION
The high-dose phytoestrogen preparation consisted of 30 g of
soy protein (70% proteins) containing 66mg of phytoestrogens
and the isolated soy protein preparation contained 0mg
of phytoestrogens. Analysis of study material confirmed
12% glycitein, 35% daidzein, and 53% genistein. 10% of
phytoestrogens were as aglycones or acetyl and malonyl
glucosides forms whereas remaining 90% of phytoestrogens were
in the primary glucoside form. Isolated soy protein preparation
consisted of less than 300 parts per billion of isoflavones,
achieved by serial alcohol washing (Dishman Ltd, India). This
was confirmed analytically by FERA, Sand Hutton, York, UK.
The phytoestrogens (Solgen40) and soy protein (SolconF) were
supplied by Solbar Ltd, Israel, and was prepared by Essential
Nutrition, Ltd, UK, who randomized the preparations.
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FIGURE 1 | Flow chart of study.
STUDY MEASUREMENTS
At the start and finish of each phase, following an overnight
fast, blood pressure (BP) and weight were measured after
which blood samples were collected. BP was measured after
the participants had been seated quietly for at least 5min
with the arm supported at heart level. BP measurements
were performed using (NPB-3900; Nellcor Puritan Bennett,
Pleasanton, CA) during study visits. Fasting venous samples
were collected, centrifuged at 2000 g at 4
◦
C for 15min. The
aliquots stored at −80
◦
C within 1 h of collection. Thyroid
hormones were performed on an Abbott Architect i4000
immunoassay analyser (Abbott Diagnostics Division, UK). The
reference range for TSH was (0.5–4.7 mU/L), free thyroxine
(9–24 pmol/L) and fT3 was (2.5–5.3 pmol/L). Urinary iodine
measurements in 24-h urine collections were undertaken by
Inductively Coupled Plasma—Mass Spectrometry to monitor for
iodine repletion. Phytoestrogen measurement was undertaken
by Liquid Chromatography–Tandem Mass Spectrometry (HFL
sport science laboratory, Cambridge, UK).
STATISTICAL ANALYSIS
For statistically significant reduction in fT4, a sample size of 40
participants in a cross over design gave 80% power to detect a
mean decrease of 0.4nmol/L of free thyroxine, with a 2-sided
alpha error of 0.05 (24).
Wilcoxon’s signed-rank test was used to data that
violated the assumptions of normality by the Kolmogorov-
Smirnov test. The carry over and period effect that may
have occurred were tested using the appropriate Student’s
t-test. Plasma phytoestrogen levels after wash out and
after 0 mg/16mg phytoestrogens were compared using
independent samples t-test. Statistical analysis was performed
using SPSS 14.0. The data is reported as mean ± SEM.
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TABLE 1 | Participant characteristics and effects on cardiovascular risk at the start of the trial and 8 weeks after supplementation.
Soy protein and isoflavone (SPI) Soy protein alone (SP) SPI–SP
Baseline 8 weeks P-value Baseline 8 weeks P-value p-value
Weight 87.6 ± 2.8 87.9 ± 2.9 0.39 87.0 ± 3.1 86.9 ± 3.0 0.56 0.28
BMI 30.1 ± 1.0 30.2 ± 1.0 0.34 30.4 ± 1.1 30.8 ± 1.1 0.57 0.30
SBP 134.0 ± 3.1 129.7 ± 2.8 0.10 132.0 ± 3.5 131.7 ± 3.2 0.91 0.74
DBP 83.5 ± 2.0 82.1 ± 2.4 0.59 80.6 ± 2.4 80.0 ± 2.0 0.75 0.12
BMI, body mass index (kg/m2); SBP, systolic blood pressure in (mmHg); DBP, diastolic blood pressure (mmHg).
TABLE 2 | Thyroid function tests and serum isoflavone levels at the start and 8 weeks after supplementation.
Soy protein and isoflavone (SPI) Soy protein alone (SP) SPI-SP
Baseline 8 weeks P value Baseline 8 weeks P value P value
fT3 4.7 ± 0.2 4.7 ± 0.1 0.92 4.6 ± 0.2 4.3 ± 0.1 0.16 0.07
fT4 11.3 ± 0.3 11.9 ± 0.3 0.12 12.2 ± 0.3 12.0 ± 0.3 0.33 1.00
TSH 5.3 ± 0.6 5.5 ± 0.4 0.70 5.0 ± 0.3 5.2 ± 0.4 0.32 0.13
Daidzein 2.2 ± 0.4 41.0 ± 7.7 <0.01 2.4 ± 0.9 2.1 ± 0.6 0.40 <0.01
Genistein 2.6 ± 0.8 172.2 ± 40.4 <0.01 2.3 ± 0.6 2.4 ± 0.9 0.20 <0.01
fT3, free triiodothyronine (T3) (pmol/L); fT4, free thyroxine (T4) (pmol/L); TSH, Thyroid Stimulating Hormone (mU/L); Daidzein (ng/ml); Genistein (ng/ml).
There were no changes in anthropometric parameters including body mass index, waist circumference or hip circumference after 66mg or 0mg phytoestrogen supplementation.
We assumed an arbitrary level of 5% statistical significance
(two-tailed).
RESULTS
Mean age of participant was 57.6 ± 1.8 years. 20 male and
24 female subjects with subclinical hypothyroidism participated
in the study. Mean body mass index of patients was 30.4 ±
1.0 kg/m2, systolic blood pressure was 132.4 ± 3.2 mmHg and
diastolic blood pressure of 80.9 ± 2.3 mmHg (Table 1). The
marker for autoimmune thyroid dysfunction, TPO antibodies,
was positive (>75u/mL) in 17 (38.6%) patients. Compliance was
98% in the study.
Two participants (6%) developed overt hypothyroidism, both
after high dose (66mg) phytoestrogen. Both of them were TPO
antibody negative. One of them was a 59 year old female with
a baseline TSH of 6.8 mU/L and the other a 71 year old male
subject with a baseline TSH of 7.1 mU/L. These two patients
developed overt hypothyroidism during their study visit after 8
weeks phytoestrogen supplementation. They had a raised TSH of
greater than 10 mIU/L, and a fT4 of less than 9pmol/L and were
symptomatic. These two patients were started on levo-thyroxine,
which was continued after 6months since repeat thyroid function
tests did not show over-replacement.
There was a significant change in daidzein and genistein
(Table 2) after high-dose phytoestrogen and no changes after
isolated soy protein supplementation. The mean TSH, fT4 and
fT3 were not different after within or between groups comparing
high dose or isolated soy protein supplementation (Table 2).
There was no carry over or period effects in any of the parameters.
There were no changes in TPO antibody positivity before or after
either supplements.
DISCUSSION
Following a pharmacological dose of soy phytoestrogens,
there were no changes in thyroid function; however, two
participants developed hypothyroidism after the high dose
phytoestrogen phase, both of whom were TPO antibody
negative. In a prospective study assessing the spontaneous
course of hypothyroidism in females, 5.6% women per
annum progressed from subclinical hypothyroidism to overt
hypothyroidism (25) and therefore it was expected that in our
study population one case per year would have progressed to
overt hypothyroidism. Compared to the previous study using
2mg and 16mg phytoestrogen, it was expected that a larger
number of patients (minimum of 3) would have developed overt
hypothyroidism (26), suggesting that the pharmacological dose
of soy phytoestrogens appeared not to confer a greater risk than
the lower dose phytoestrogen levels.
Compared to the previous study using 2mg and 16mg
phytoestrogen, it was expected that a larger number of patients
would have developed overt hypothyroidism (13). This could
be due to several reasons including relatively larger number
of dropouts compromising the power of the study. Also there
were more males (45.4%) in this study compared to 13% in
the previous study (13). This is supported by community-based
cross-sectional study in China which revealed intake of soy
protein and isoflavones was inversely associated with number of
cardiometabolic disturbances amongwomen but not inmen (27).
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Another important factor which could have contributed to the
results was that the patient group in this study was less sensitive
to the hypothyroid effects of soy phytoestrogen as compared
to the previous study (13) because of having low average TSH
values (5.3 ± 0.6 mU/L in this study as compared to high
serum TSH values (7.8 ± 0.4 mU/L) in the first part of study
(13). As it has been shown previously that the level of serum
TSH is an important risk factor for the development of overt
hypothyroidism and increased risk in patients who have TSH
values >6 mU/L as compared to patients who have TSH values
<6 mU/L (25, 28). 61% of participants had antibody negative
subclinical hypothyroidism. We did not perform ultrasound of
thyroid in the participants.
Isoflavones have shown to inhibit thyroid peroxidase which
is an enzyme involved in the synthesis of T3 and T4 (18).
Fischer rat thyroid cells (FRTL) when treated with soy protein
and isoflavones; there was a dose dependent suppression
of iodide uptake in FRTL cells whereas isoflavone alone
was not effective. Soy protein and isoflavone increased non-
glycosylated sodium/iodide symporter (NIS) and the 40 kDa
thyroglobulin fragment which is a known autoimmunogen
in the FRTL cells that potentially contributes to thyroid
dysfunction (29).
We have previously reported that using this soy preparation
with 66mg of isoflavones caused a small though significant
increase in TSH and decrease in fT4 in men and women with
thyroid function tests within the reference range, though likely
this would not be clinically significant (30, 31). The results of this
study suggest that no further incremental deterioration in either
TSH or fT4 occurs in compensated hypothyroidism.
In conclusion, it is reassuring that a pharmacological dose
of 66mg soy phytoestrogens was not associated with either
a deterioration of thyroid function or an increased rate of
thyroid failure over an 8 week period, above that associated with
commonly ingested soy quantities.
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